V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210002938 | 210006388 | 1.53 | 58 | Adjuvant (A) | 2020-01-03 | 2020-01-19 | EC | 02 | N | EC | 100980142 |
| 210002942 | 210006391 | null | null | null | 2017-03-17 | 2017-04-04 | FEC 100 | null | null | FEC | 101053988 |
| 210002944 | 210006393 | 1.65 | 62.7 | Adjuvant (A) | 2017-08-11 | 2017-08-31 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | LETROZOLE + PALBOCICLIB | 101520382 |
| 210002946 | 210006395 | null | 70.9 | null | 2018-10-23 | 2018-10-29 | Paclitaxel+Trastuzumab wkly Maint | N | null | PACLITAXEL + TRASTUZUMAB | 101757854 |
| 210002951 | 210006398 | 1.61 | 80.4 | Neo-adjuvant (N) | 2017-06-24 | 2017-07-06 | null | 02 | N | CAPECITABINE | 100080202 |
| 210002955 | 210006399 | null | null | Adjuvant (A) | 2017-11-03 | 2017-11-19 | null | null | N | ERIBULIN | 101446142 |
| 210002959 | 210006403 | 1.64 | 90.7 | Neo-adjuvant (N) | 2019-04-26 | 2019-07-21 | FEC 100 | 02 | N | FEC | 101277081 |
| 210002960 | 210006404 | 1.58 | 81 | Adjuvant (A) | 2019-08-31 | 2019-09-01 | null | 02 | null | LETROZOLE + PALBOCICLIB | 101632300 |
| 210002961 | 210006405 | 1.64 | 69.7 | Palliative (P) | 2017-06-30 | 2017-07-10 | null | null | N | CAPECITABINE | 100315730 |
| 210002963 | 210006407 | null | null | null | 2018-07-10 | 2018-07-17 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 100415447 |
| 210002971 | 210006411 | 1.55 | 94.6 | Neo-adjuvant (N) | 2016-03-31 | 2016-04-15 | FEC 100 | N | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101127094 |
| 210002973 | 210006412 | 1.62 | 76.9 | null | 2019-12-10 | 2019-12-15 | EC | 02 | null | EC | 100264860 |
| 210002975 | 210006413 | 1.7 | 111.9 | Adjuvant (A) | 2018-07-07 | 2018-07-16 | FEC | 02 | N | FEC | 100131869 |
| 210002976 | 210006414 | 1.58 | 80.4 | Adjuvant (A) | 2018-12-18 | 2019-01-04 | FEC 100 | null | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100655685 |
| 210002977 | 210006415 | 1.64 | 68.6 | Palliative (P) | null | 2019-09-12 | FEC 100 | 02 | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100194669 |
| 210002980 | 210006416 | 1.64 | 95 | Neo-adjuvant (N) | 2019-03-07 | 2019-03-22 | null | 02 | N | CAPECITABINE | 100107938 |
| 210002981 | 210006417 | null | 127 | null | null | 2018-06-24 | FEC + DOCETAXEL | N | null | FEC + DOCETAXEL | 100282179 |
| 210002982 | 210006418 | 1.57 | 84.8 | Adjuvant (A) | 2017-06-17 | 2017-06-18 | null | N | N | NAB-PACLITAXEL | 101036882 |
| 210002983 | 210006419 | null | null | null | 2019-08-27 | 2019-09-07 | FEC 60 OR 75 + DOCETAXEL | null | null | FEC + DOCETAXEL | 100403952 |
| 210002992 | 210006426 | 1.6 | 56 | Neo-adjuvant (N) | 2018-12-13 | 2019-03-04 | Paclitaxel+Trastuzumab wkly Maint | null | N | PACLITAXEL + TRASTUZUMAB | 101079367 |
| 210002995 | 210006428 | 1.68 | 90.7 | Neo-adjuvant (N) | 2018-07-08 | 2018-07-08 | EC | null | N | EC | 101832415 |
| 210002998 | 210006430 | 1.66 | 76.9 | Palliative (P) | 2018-12-19 | 2019-01-09 | null | null | N | EPIRUBICIN | 101435951 |
| 210003000 | 210006432 | 1.68 | 76.7 | Neo-adjuvant (N) | 2016-07-02 | 2016-07-09 | FEC | N | N | FEC | 101053721 |
| 210003008 | 210006440 | null | null | null | 2016-12-24 | 2017-01-02 | CAPECITABINE + PACLITAXEL | null | null | CARBOPLATIN + PACLITAXEL | 101558070 |
| 210003016 | 210006445 | null | null | null | 2015-01-24 | 2016-04-06 | null | N | null | TCH | 100260629 |
| 210003021 | 210006448 | 1.62 | 55 | Adjuvant (A) | 2019-07-14 | 2019-07-22 | TRASTUZUMAB EMTANSINE | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + PACLITAXEL + TRASTUZUMAB | 101517375 |
| 210003023 | 210006449 | 1.81 | 59.1 | Palliative (P) | null | 2018-04-13 | FEC + DOCETAXEL | null | N | CYCLOPHOSPHAMIDE + DOCETAXEL + EPIRUBICIN + FLUOROURACIL | 100005025 |
| 210003027 | 210006452 | 1.62 | 62.7 | Palliative (P) | null | 2019-10-24 | ATEZOLIZUMAB + NAB PACLITAXEL | 02 | N | TRIAL UNSPECIFIED | 101389681 |
| 210003031 | 210006456 | null | 76.5 | Neo-adjuvant (N) | 2017-03-06 | 2017-03-06 | EC | null | N | EC | 100220188 |
| 210003034 | 210006457 | null | null | null | 2019-10-20 | 2019-10-21 | null | null | null | CARBOPLATIN | 101051849 |
| 210003038 | 210006460 | 1.65 | 60 | Adjuvant (A) | 2018-05-13 | 2018-05-19 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | N | CARBOPLATIN + DOCETAXEL + TRASTUZUMAB | 101211322 |
| 210003041 | 210006462 | 1.64 | 72 | Adjuvant (A) | null | 2017-03-31 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100486645 |
| 210003043 | 210006464 | null | 100.3 | Adjuvant (A) | 2017-08-22 | 2018-02-27 | Epirubicin (weekly) | 02 | N | CAPECITABINE | 100052869 |
| 210003047 | 210006465 | 1.6 | 59 | Adjuvant (A) | 2017-01-24 | 2017-02-08 | FEC 100 | null | N | FEC | 101063761 |
| 210003052 | 210006469 | null | 71.6 | null | 2020-01-26 | 2020-01-30 | FEC | 02 | null | FEC | 101098094 |
| 210003054 | 210006471 | null | null | null | null | 2019-03-03 | null | 02 | null | VINORELBINE | 101102922 |
| 210003055 | 210006472 | null | null | null | null | 2017-01-27 | FEC 100 | N | null | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101391093 |
| 210003056 | 210006473 | 0 | 96.6 | null | null | 2017-01-02 | null | 02 | null | CARBOPLATIN + GEMCITABINE | 100671265 |
| 210003064 | 210006480 | 1.58 | 94 | Adjuvant (A) | 2018-04-27 | 2018-04-28 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101238725 |
| 210003067 | 210006483 | 1.49 | 64.9 | Palliative (P) | 2018-06-16 | 2018-06-28 | FEC 100 | 01 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 101080806 |
| 210003071 | 210006487 | 0 | 64.95 | Neo-adjuvant (N) | null | 2017-08-15 | FEC + DOCETAXEL | 02 | N | FEC + DOCETAXEL | 100420339 |
| 210003072 | 210006488 | 0 | 61.15 | Adjuvant (A) | null | 2019-07-09 | FEC + DOCETAXEL | null | N | FEC + DOCETAXEL | 100458010 |
| 210003076 | 210006491 | 1.64 | 62.3 | Adjuvant (A) | null | 2016-04-15 | null | 02 | N | TRIAL UNSPECIFIED | 100182857 |
| 210003080 | 210006494 | 1.69 | 83.6 | Palliative (P) | null | 2017-09-02 | FEC + DOCETAXEL | N | N | FEC + DOCETAXEL | 101359076 |
| 210003081 | 210006495 | null | 69.2 | null | 2022-03-28 | 2022-03-28 | null | 02 | null | CAPECITABINE | 101022581 |
| 210003082 | 210006496 | 1.68 | 54.8 | Palliative (P) | 2018-10-29 | 2018-11-01 | FEC | null | N | FEC | 101529996 |
| 210003084 | 210006498 | 1.58 | 0 | Palliative (P) | 2017-12-22 | 2017-12-22 | Fulvestrant + Palbociclib | 02 | N | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | 101656772 |
| 210003086 | 210006500 | 1.57 | 74.8 | Palliative (P) | 2016-07-20 | 2016-07-23 | FEC 100 | 02 | N | CYCLOPHOSPHAMIDE + EPIRUBICIN + FLUOROURACIL | 100824734 |
| 210003087 | 210006501 | 1.64 | 60.8 | null | 2019-01-28 | 2019-02-13 | FEC 60 or 75 | N | null | FEC | 100332921 |
| 210003089 | 210006503 | 1.62 | 81 | Palliative (P) | 2021-04-17 | 2021-04-30 | Paclitaxel+Trastuzumab wkly Maint | 02 | null | PACLITAXEL + TRASTUZUMAB | 101848035 |